This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety endpoint (Part 1)- Adverse Event（AEs）
Timeframe: up to 2 years from Eque-cel infusion
Safety endpoint (Part 1)-CRS
Timeframe: up to 2 years from Eque-cel infusion
Safety endpoint (Part 1)-ICANS
Timeframe: up to 2 years from Eque-cel infusion
Efficacy endpoint (Part 2): Independent Review Committee (IRC)-assessed ORR
Timeframe: up to 2 years from Eque-cel infusion